NT-0796 shows sustained easing of inflammation in Phase 1/2 trial
NodThera’s potential oral therapy for Parkinson’s disease, NT-0796, continues to show promise in countering damaging inflammation in treated…
Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
NodThera’s potential oral therapy for Parkinson’s disease, NT-0796, continues to show promise in countering damaging inflammation in treated…
Patient enrollment has started in a Phase 1/2 clinical trial evaluating 18F-OP-801, Ashvattha Therapeutics’ investigational imaging agent…
Targeting reactive astrocytes — star-shaped cells in the brain that play a supportive role for neurons but can promote…
A potential anti-inflammatory therapy for Parkinson’s disease may be evaluated in clinical trials within the next year. The investigative…
An observational clinical trial in Canada that’s investigating the role of the small intestinal microbiome — the population of natural…
A first participant has been dosed in Arvinas’ first-in-human Phase 1 trial testing ARV-102, its oral therapy candidate for neurodegenerative…
Computer scientists at the University of North Carolina at Chapel Hill have developed software and an augmented reality (AR) headset…
Suppressing astrocytes’ release of the pro-inflammatory molecule interleukin (IL)-6 reduced the loss of dopaminergic neurons, the nerve cells that are…
A natural chemical modification — called O-GlcNAc — that occurs in specific building blocks of the alpha-synuclein protein can lessen…
The department of neurology at Vanderbilt University Medical Center (VUMC) is now part of the CurePSP Center of Care…
Get regular updates to your inbox.